CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 45 enrolled
Drug / intervention
Pyridostigmine Bromide +1 moredrug
Likely dose
Pyridostigmine Bromide 60 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03674541
NCT03674541Phase 2Completed

The Exercise Response to Pharmacologic Cholinergic Stimulation in Myalgic Encephalomyelitis / Chronic Fatigue Syndrome

Brigham and Women's Hospital·interventional·Posted Sep 17, 2018·Updated Nov 8, 2022

In Brief

A Phase 2 clinical trial evaluating Pyridostigmine Bromide and Placebo for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and 8 related conditions. Completed, enrolled 45 participants across 1 site.

Detailed Summary

Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS), otherwise known as Chronic fatigue syndrome (CFS) or myalgic encephalomyelitis (ME), is an under-recognized disorder whose cause is not yet understood. Suggested theories behind the pathophysiology of this condition include autoimmune causes, an inciting viral illness, and a dysfunctional autonomic nervous system caused by a small fiber polyneuropathy. Symptoms include fatigue, cognitive impairments, gastrointestinal changes, exertional dyspnea, and post-exertional malaise. The latter two symptoms are caused in part by abnormal cardiopulmonary hemodynamics during exercise thought to be due to a small fiber polyneuropathy. This manifests as low biventricular filling pressures throughout exercise seen in patients undergoing an invasive cardiopulmonary exercise test (iCPET) along with small nerve fiber atrophy seen on skin biopsy. After diagnosis, patients are often treated with pyridostigmine (off-label use of this medication) to enhance cholinergic stimulation of norepinephrine release at the post-ganglionic synapse. This is thought to improve venoconstriction at the site of exercising muscles, leading to improved return of blood to the heart and increasing filling of the heart to more appropriate levels during peak exercise. Retrospective studies have shown that noninvasive measurements of exercise capacity, such as oxygen uptake, end-tidal carbon dioxide, and ventilatory efficiency, improve after treatment with pyridostigmine. To date, there are no studies that assess invasive hemodynamics after pyridostigmine administration. It is estimated that four million people suffer from ME/CFS worldwide, a number that is thought to be a gross underestimate of disease prevalence. However, despite its potential for debilitating symptoms, loss of productivity, and worldwide burden, the pathophysiology behind ME/CFS remains unknown and its treatment unclear. By evaluating the exercise response to cholinergic stimulation, this study will shed further light on the link between the autonomic nervous system and cardiopulmonary hemodynamics, potentially leading to new therapeutic targets.

Study Details

Timeline

Phase 2CompletedFinished
20192020202120222023202420252026
First PostedSep 17, 2018
Enrollment StartJan 14, 2020
Primary CompletionDec 5, 2021
Study CompletionDec 20, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.8 years ago

Interventions

Pyridostigmine Bromidedrug

Pyridostigmine Bromide 60 mg capsule by mouth as a one time dose

Placebodrug

Placebo (Cellulose microcrystalline) capsule by mouth as a one time dose